Search results for "primary biliary cirrhosis"

showing 10 items of 61 documents

Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage

2020

Recent series have demonstrated advantages of living donor over deceased donor liver transplantation, with particular benefit for those with low model for end-stage liver disease score. The logic underlying the transplantation of patients before they become too sick is intuitive. It reduces mortality and drop outs from the waiting list and makes transplant surgery less demanding. Those principles have to be balanced with donor safety and transplant benefit for the recipient avoiding early, futile transplantation. The authors report a case of adult to adult right lobe living donor liver transplantation performed for a recipient affected by primary biliary cirrhosis with MELD score of 15, in …

MalePhysiologymedicine.medical_treatmentLiver transplantationSeverity of Illness IndexLiver diseasePostoperative Complications0302 clinical medicinePrimary biliary cirrhosisTransplant surgeryLiving DonorsLiver Transplantation.Liver resectionLiver Cirrhosis BiliaryGastroenterologyCone-Beam Computed TomographyMiddle AgedTreatment Outcomesurgical procedures operativeItalyLiver030220 oncology & carcinogenesisFemaleRisk Adjustment030211 gastroenterology & hepatologyLiving donor liver transplantationHumanAdultmedicine.medical_specialtyTissue and Organ ProcurementClinical Decision-MakingTime-to-TreatmentEnd Stage Liver Disease03 medical and health sciencesInternal medicineSeverity of illnessmedicineHepatectomyHumansIntensive care medicineLiver transplantationbusiness.industryLiving donor liver transplantationHepatologymedicine.diseasePleural EffusionTransplantationSurgeryPostoperative Complicationbusiness
researchProduct

Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress

2004

Ursodeoxycholic acid (UDCA) improves clinical and biochemical indices in primary biliary cirrhosis and prolongs survival free of liver transplantation. Recently, it was suggested that the cytoprotective mechanisms of UDCA may be mediated by protection against oxidative stress, which is involved in the development of cirrhosis induced by chronic cholestasis. The aims of the current study were 1) to identify the mechanisms involved in glutathione depletion, oxidative stress, and mitochondrial impairment during biliary cirrhosis induced by chronic cholestasis in rats; and 2) to determine the mechanisms associated with the protective effects of UDCA against secondary biliary cirrhosis. The find…

Malemedicine.medical_specialtyCirrhosisCardiolipinsGlutamate-Cysteine LigaseBiliary cirrhosisPopulationBiologymedicine.disease_causeMembrane Potentialschemistry.chemical_compoundPrimary biliary cirrhosisInternal medicinemedicineCardiolipinAnimalsRats Wistareducationeducation.field_of_studyCholestasisHepatologyLiver Cirrhosis BiliaryUrsodeoxycholic AcidCystathionine gamma-LyaseGlutathionemedicine.diseaseGlutathioneUrsodeoxycholic acidMitochondriaPeroxidesRatsOxidative StressEndocrinologyLiverchemistryChronic DiseaseHepatocytesOxidation-ReductionOxidative stressmedicine.drugHepatology
researchProduct

Effect of different doses of ursodeoxycholic acid in chronic liver disease

1989

Recent clinical studies have indicated that ursodeoxycholic acid (ursodiol), administered at dosages ranging between 10 and 15 mg/kg/day, improves liver function indices in both cholestatic and inflammatory chronic liver diseases. These dosages would be considered high for the use of ursodiol in gallstone dissolution therapy. To investigate the dose-response relationship to ursodiol administration, we planned a few studies in patients with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and chronic hepatitis (CH). Patients with PBC were subdivided into two groups on the basis of their serum bilirubin values, with 2 mg/dl as the dividing line. Ursodiol was given at dos…

Malemedicine.medical_specialtyTime FactorsPhysiologyBilirubinCholangitis SclerosingChronic liver diseaseGastroenterologyPrimary sclerosing cholangitisRandom Allocationchemistry.chemical_compoundPrimary biliary cirrhosisLiver Function TestsInternal medicinemedicineBileHumansHepatitis ChronicHepatitisDose-Response Relationship Drugmedicine.diagnostic_testLiver Cirrhosis Biliarybusiness.industryUrsodeoxycholic AcidGastroenterologyBilirubinMiddle AgedLipid Metabolismmedicine.diseaseUrsodeoxycholic acidchemistryFemaleLiver functionLiver function testsbusinessDeoxycholic Acidmedicine.drugDigestive Diseases and Sciences
researchProduct

Significant autoimmune markers of autoimmune liver disorders: Current status

1987

Microbiology (medical)Hepatitisbusiness.industryBiochemistry (medical)Clinical BiochemistryPublic Health Environmental and Occupational HealthAutoantibodyHematologymedicine.disease_causemedicine.diseaseAutoimmunityMedical Laboratory TechnologyPrimary biliary cirrhosisImmunologymedicineImmunology and AllergybusinessJournal of Clinical Laboratory Analysis
researchProduct

2015

AbstractPrimary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined<5 × 10−8) and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine–cytokine pathways, for which relevant therapies exist.

MultidisciplinaryGeneral Physics and AstronomySingle-nucleotide polymorphismGenome-wide association studyGeneral ChemistryBiologymedicine.diseaseBioinformaticsGeneral Biochemistry Genetics and Molecular Biology3. Good healthPrimary biliary cirrhosisMeta-analysisGenotypeImmunologymedicineGenetic predispositionGenotypingGenetic associationNature Communications
researchProduct

Serum antibodies to thymus epithelial cells in non-A, non-B and cryptogenic chronic liver disease

2008

Antibodies against thymus epithelial cells (anti-TEC) and the basal cell layer (BCLA) of squamous epithelia have been described in association with HDV-related chronic liver disease (CLD). Data are lacking on their presence during nAnB virus infection. Sera from 51 patients with nAnB post-transfusion hepatitis, including acute and chronic cases diagnosed during a prospective study on candidates for cardiac surgery, and 167 with various forms of CLD were tested for the presence of anti-TEC and BCLA using indirect immunofluorescence on human thymus and rat forestomach sections. Both antibodies mainly occurred in nAnB, HDV and cryptogenic CLD (anti-TEC: 51%, 47% and 42%; BCLA: 29%, 38% and 31%…

Pathologymedicine.medical_specialtyHepatitis Viral Humanmedicine.drug_classFluorescent Antibody TechniqueThymus GlandChronic liver diseaseMonoclonal antibodyEpitheliumSerologyPrimary biliary cirrhosisAntigenAntibody SpecificitymedicinePrevalenceHumansProspective StudiesChildAutoantibodiesHepatitis ChronicHepatitisHepatologybiologyLiver DiseasesAutoantibodyAntibodies MonoclonalTransfusion Reactionmedicine.diseaseHepatitis CImmunologyAcute Diseasebiology.proteinKeratinsAntibody
researchProduct

In vitro secretion of specific antimitochondrial antibodies in primary biliary cirrhosis

1992

Antimitochondrial antibodies are present in the serum of virtually all patients with primary biliary cirrhosis. They have a well-defined antigen reactivity that is diagnostic for the disease. The role of these autoantibodies in the disease process remains to be defined. In this study we show that antimitochondrial antibodies can be produced in vitro by peripheral blood lymphocytes, that the cells producing antimitochondrial antibodies are present in the peripheral blood in a high frequency and seem to be maximally activated. Stimulation with pokeweed mitogen did not augment the in vitro production of antimitochondrial antibodies in patients nor did it induce the production of these antibodi…

Pathologymedicine.medical_specialtyLymphocyteImmunoblottingRadioimmunoassayEnzyme-Linked Immunosorbent AssayPrimary biliary cirrhosisAntigenAntibody SpecificitymedicineHumansCells CulturedAutoantibodiesHepatologybiologyLiver Cirrhosis Biliarybusiness.industryPokeweed mitogenAutoantibodyRadioimmunoassaymedicine.diseaseMitochondriamedicine.anatomical_structurePolyclonal antibodiesImmunologybiology.proteinAntibodybusinessJournal of Hepatology
researchProduct

Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist

2013

Primary biliary cirrhosis is a slowly progressive cholestatic autoimmune liver disease that mainly affects middle- aged women with an estimated prevalence ranging from 6.7 to 402 cases per million. Hereditary hemorrhagic telangiectasia, or Rendu-Osler-Weber disease, is an autosomal dominant disorder characterized by angiodysplastic lesions (telangiectases and arteriovenous malformations) that can affect many organs, including liver, with a prevalence of 1-2 cases per 10000. We describe the coexistence, for the first time to our knowledge, of these two rare diseases in a 50-year old Caucasian woman. In this setting, the relevance of an accurate medical history, the role of liver histology an…

Pathologymedicine.medical_specialtySettore MED/12 - GastroenterologiaPrimary biliary cirrhosiHepatologybusiness.industryFocal nodular hyperplasiaCase ReportDiseaseTelangiectasesImmunostainingSettore MED/08 - Anatomia Patologicamedicine.diseaseUrsodeoxycholic acidPrimary biliary cirrhosisHereditary hemorragic telangiectasiaUrsodeoxycholic acidFocal nodular hyperplasiamedicineMedical historymedicine.symptomAutoimmune liver diseasebusinessTelangiectasiamedicine.drug
researchProduct

HUMAN LEUKOCYTE ANTIGEN POLYMORPHISMS IN ITALIAN PRIMARY BILIARY CIRRHOSIS: A MULTICENTER STUDY OF 664 PATIENTS AND 1992 HEALTHY CONTROLS

2008

Genetic factors are critical in determining susceptibility to primary biliary cirrhosis (PBC), but there has not been a clear association with human leukocyte antigen (HLA) genes. We performed a multicenter case-control study and analyzed HLA class II DRB1 associations using a large cohort of 664 well-defined cases of PBC and 1992 controls of Italian ancestry. Importantly, healthy controls were rigorously matched not only by age and sex, but also for the geographical origin of the proband four grandparents (Northern, Central, and Southern Italy). After correction for multiple testing, DRB1*08 [odds ratio (OR), 3.3; 95% confidence interval (CI), 2.4-4.5] and DRB1*02 (OR 0.9; 95% CI 0.8-1.2) …

ProbandLiver CirrhosisMaleCohort StudiesPrimary biliary cirrhosisGene FrequencyModelsGenotype80 and overMedicineskin and connective tissue diseasesAged 80 and overSettore MED/12 - GastroenterologiaLiver Cirrhosis BiliaryMedicine (all)BiliaryMiddle AgedItalyHLA-DRB1 ChainFemaleCase-Control StudieHumanmusculoskeletal diseasesAdultGenotypeHuman leukocyte antigenArticleGeneticGenetic modelHumansGenetic Predisposition to DiseasePolymorphismAllele frequencyAgedPolymorphism GeneticHepatologyModels Geneticbusiness.industryCase-control studyOdds ratioHLA-DR Antigensmedicine.diseaseHLA-DR AntigenAdult; Aged; Aged 80 and over; Case-Control Studies; Cohort Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; HLA-DR Antigens; Humans; Italy; Liver Cirrhosis Biliary; Male; Middle Aged; Models Genetic; Polymorphism GeneticCase-Control StudiesImmunologyprimary bilairy cirrhosis geneticsCohort StudiebusinessHLA-DRB1 Chains
researchProduct

Clinical relevance of antiphospholipid antibodies in primary biliary cirrhosis.

2005

Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies (AMAs), but also with reactivities to other autoantigens. Recent studies showed that antibodies to phospholipids (APAs) represent an important group of autoantibodies identified in patients with PBC. In this study different types of APAs were identified in the sera of patients with PBC and autoimmune hepatitis (AIH) and control subjects. Sera from patients with PBC and AIH were tested for the presence of antibodies directed against cardiolipin (CL), phosphatidylserine (PS), and to beta(2)-glycoprotein I (beta(2)-GPI). Furthermore, an in-house test for antithrombop…

biologyAnti-nuclear antibodybusiness.industryLiver Cirrhosis BiliaryGeneral NeuroscienceAutoantibodyAutoimmune hepatitismedicine.diseasedigestive system diseasesGeneral Biochemistry Genetics and Molecular BiologyHepatitis AutoimmunePrimary biliary cirrhosisHistory and Philosophy of ScienceImmunoglobulin MImmunoglobulin MImmunologybiology.proteinAntibodies AntiphospholipidMedicineAlkaline phosphataseHumansClinical significanceAntibodyskin and connective tissue diseasesbusinessAnnals of the New York Academy of Sciences
researchProduct